Methanol extract from radix of *Glycyrrhiza uralensis* attenuate methamphetamine-induced hyperlocomotor activity

ZhengLin Zhao¹ · Yan Wang¹ · Feng Lin¹ · Hui Fu¹ · FuBo Zhou¹ · Suchan Chang² · Nu Ri Han² 
· Dae Hwa Jung² · Chae Ha Yang² · Sang Chan Kim²* · RongJie Zhao¹,²*  

¹Department of Pharmacology, Mudanjiang Medical University, Mudanjiang, China · ²MRC-GHF, Daegu Haany University, Gyeongsan, Korea

**ABSTRACT**

**Background and objective:** Methamphetamine (Meth) is a widely abused psychostimulant that produces hyperlocomotion in rodents. Radix of *Glycyrrhiza uralensis* comprises a variety of bioactive components that have neuroprotective effects. In a previous study, we have demonstrated methanol extracts from radix of *Glycyrrhiza uralensis* (MEGR) suppress acute cocaine-induced extracellular dopamine release in the nucleus accumbens. In the present study, we investigated the effect of MEGR on acute Meth-induced hyperlocomotion.  

**Methods:** Male Sprague-Dawley rats were orally administered with MEGR (60 mg/kg and 180 mg/kg) 60 min prior to an intraperitoneal injection of Meth (1.0 mg/kg).  

**Results:** Behavioral analysis showed acute Meth greatly increased locomotor activities, while pretreatment
with MEGR dose dependently inhibited the hyperlocomotion. In parallel, there were markedly increased levels of dopamine and its metabolite 3, 4-dihydroxyphenylacetic acid in the nucleus accumbens tissues in Meth-treated rats, which were also almost completely reversed by 180 mg/kg MEGR.

**Conclusions:** These results showed that radix of *Glycyrrhiza uralensis* attenuates Meth-induced hyperlocomotion by inhibiting dopamine synthesis and utilization, suggesting that radix of *Glycyrrhiza uralensis* might be effective in blocking the rewarding effect of Meth.

**Keyword:** Methamphetamine, *Glycyrrhiza uralensis*, Locomotion, Dopamine, Nucleus accumbens

## I. Introduction

Although methamphetamine (Meth) dependence is a serious worldwide public health problem with major medical, psychiatric, socioeconomic and legal consequences [1], there is currently no FDA approved pharmacotherapy for this addictive disorder. The rewarding effects of Meth including euphoria and many other psychostimulant effects are the mainstay to sustain the continued use of Meth, ultimately lead to Meth addiction [2]. Therefore, nullifying the rewarding effects of Meth is a promising approach to treat Meth addiction.

It is well documented that the commonly abused psychostimulants including Meth increase locomotor activity in rodents, and the biological mechanisms of this stimulant action are homologous with their rewarding effects [3]. Convincing evidence shows that the rewarding effects of Meth mainly come from enhanced dopaminergic neurotransmissions in the mesolimbic and mesocortical brain regions such as the ventral tegmental area, the nucleus accumbens (Nacc) and the medial prefrontal cortex, which also mediate Meth-induced hyperlocomotion [4]. Therefore, inhibition on the increased dopaminergic activities in the mesolimbic brain regions biochemically prevents the formation of the biological bases for Meth addiction and behaviorally blocks hyperlocomotion induced by Meth. For example, a selective dopamine (DA) 1 receptor antagonist SCH23390 injection into the Nacc attenuates Meth-induced hyperlocomotion in rats [5], Limonene inhibits Meth-induced increased locomotor activity via regulation of enhanced accumbal DA release [6].

Radix of *Glycyrrhiza uralensis* (G. radix), one of the oldest and most popularly used botanicals in traditional Oriental medicine, contains flavonoids and pentacyclic triterpene saponin as major constituents, which include liquiritigenin, isoliquiritigenin, liquiritin, liquiritin apioside, and glycyrrhizin [7]. Being an important tonic, G. radix is generally used to replenish and invigorate deficient Qi and blood, and widely recommended for life-enhancing properties and cure of injury or swelling and for detoxification [8]. Historically, most experimental studies on pharmacological values of G. radix were devoted to its anti-inflammatory and anti-oxidative properties [9, 10], however, over the last decade, numerous reports from various laboratories have emphasized the neuropharmacological properties of G. radix, and these reports point to the

---

# Authors contributed equally.

* Corresponding author : Sang Chan Kim, Daegu Haany University, #1, Hanuidae-ro, Gyeongsan-si, Gyeongsangbuk-do, 712–715, South Korea.
  ‧ Tel : 82–53–819–1863
  ‧ E-mail: sckim@dhu.ac.kr

Rongjie Zhao, Mudanjiang Medical University, #3 Tongxiang Street, Mudanjiang, China,
  ‧ Tel : 86–453–2984682
  ‧ E-mail: zhao_rongjie@yahoo.com

* Received : May 8, 2014 / Revised : May 30, 2014 / Accepted : June 7, 2014
neuroprotective effects of G. radix and its bioactive ingredients against various noxious stimuli [11]. Most notably, studies done in our lab have shown that methanol extracts of G. radix (MEGR) and isoliquiritigenin suppress cocaine-induced extracellular dopamine release in rat Nacc through GABAb receptors [12], and isoliquiritigenin also prevents Meth-induced neurotoxicity in mouse brain by inhibiting NF-κB activation [13]. These observations conjunction with its neuroprotective effects reported by others lead to a hypothesis that G. radix have preventive effects against Meth-induced psychostimulant effects.

To test this hypothesis, in the present study we evaluate the effects of MEGR on locomotor activities and accumbal DA and 3, 4-dihydroxyphenylacetic acid (DOPAC) levels in rats following an acute Meth administration.

II. Materials and methods

1. Preparation of MEGR

The air–dried G. radix was purchased from Daewon Pharmacy (Daegu, Republic of Korea), and its identity and composition was confirmed by Professor Sang Chan Kim of the College of Oriental Medicine at Daegu Haany University in Korea. The G. radix was crushed into powder and extracted with methanol three times for 12 h each at room temperature. The extract was filtered through a 0.2 μm filter (Nalgene, NY, USA), evaporated under reduced pressure at temperature of 37 °C and lyophilized. The amount of extracts was estimated from the dry weight of lyophilized powder, and the yield was 15.39%, and the high performance liquid chromatography (HPLC) fingerprint of MEGR is shown in Fig. 1. The MEGR was dissolved in 5% Tween-80 and orally administered.

![Figure 1. The HPLC profiles of MEGR at 254 nm (liquiritigenin), 276 nm (glycyrrhizic acid), and 380 nm (isoliquiritigenin). Flow rate: 1.0 mL/min, column: Waters XTerra®RP18(150 × 4.6 mm, 5 μm)]
and immediately after the Meth the locomotor activity of each rat was measured in the box for 60 min. The box used to measure locomotor activity is a rectangular container (40 x 40 x 45 cm) equipped with a video camera above the center of the floor. The walls and floor were made of a clear plexiglas and painted black. The ambulatory distance was recorded by a videotracking system using the Ethovision program (Noldus Information Technology BV, Wageningen, Netherlands).

4. DA and DOPAC analysis

Immediately after the behavioral test, each rat was decapitated and the entire brain was moved and stored at -80°C. To determine the effects of MEGR on the Meth-induced changes of mesolimbic dopaminergic activities, the accumbal DA and DOPAC concentrations were measured using HPLC analysis. The stored brain was dissected using the coordinates of Paxinos and Watson [14] to obtain Nacc tissues(Fig. 2). The tissues were sonicated in 1 ml of 0.1 M HClO4 for 30 s, and centrifuged for 15 min at 26,000 g, 4°C. Then, a 20-µl supernatant aliquot was injected directly into the HPLC with a coulmoetric detector (Coulchem II: ESA, Bedford, MA, USA). The HPLC system consists of a C18 reverse-phase column(5 µ ODS; Altex, Ann Arbor, MI, USA) and an electrochemical transducer with a glassy carbon electrode set at 350 mV. The mobile phase was 0.16 M citric acid, pH 3.0, containing 0.02 mM EDTA with 0.69 mM sodium octanesulfonic acid as an ion-pairing reagent, 4%(v/v) acetonitrile and 1.7%(v/v) tetrahydrofurane. Peaks and values of DA and DOPAC in samples were identified and calculated by comparing their retention times and peak heights with those of standards. Results were reported as ng/g protein. The protein concentration in brain homogenate was determined by the BCA protein assay.

5. Statistical analysis

All data were expressed as means ± standard error of the mean (SEM) and statistically analyzed by one-way analysis of variance (ANOVA) followed by the Newman-Keuls multiple comparison test using the commercially available GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA, USA). A P value < 0.05 was considered to indicate statistical significance.

III. Results

1. Effects of MEGR on Meth-induced locomotor activity

Figure. 3 shows the effect of MEGR on locomotor activities. ANOVA on data from MEGR treatment revealed a significant effect [F (3, 20) = 17.8, p < 0.001]. Post hoc comparisons revealed acute Meth significantly increased locomotor activities in rats (vehicle+saline vs. vehicle+Meth, p < 0.001), while pretreatment with both doses of MEGR significantly inhibited the Meth-induced hyperlocomotion (vehicle+Meth
Zhao et al., Radix of Glycyrrhizae uralensis attenuates methamphetamine-induced hyperlocomotor activity

2. Effects of MEGR on Meth-induced changes of accumbal DA and DOPAC concentrations.

Fig. 5. shows the effects of MEGR on accumbal levels of DA and DOPAC. ANOVA and post hoc analysis showed a single dose of Meth (1 mg/kg) significantly increased both DA [F (3, 20) = 6.2, p < 0.01; vehicle+saline vs. vehicle+Meth, p < 0.01] and DOPAC [F (3, 20) = 7.5, p < 0.01; vehicle+saline vs. vehicle+Meth, p < 0.01] concentrations in the Nacc, indicating the enhanced synthesis and utilization of DA. However, similar to the behavioral results, pretreatment with 180 mg/kg MEGR significantly inhibited the increase of both DA (vehicle+Meth vs. MEGR180+Meth, p < 0.01) and DOPAC (vehicle+Meth vs. MEGR180+Meth, p < 0.01) levels, while 60 mg/kg MEGR presented no significant effects (DA: vehicle+Meth vs. MEGR60+Meth, p > 0.05; DOPAC: vehicle+Meth vs. MEGR60+Meth,
In addition, HPLC analysis also showed MEGR itself did not produce any significant impact upon accumbal DA and DOPAC levels (data not shown).

IV. Discussion

In a previous study we demonstrated MEGR suppresses cocaine–induced extracellular dopamine release in rat Nacc [12], in the present study we extended this result showing that MEGR inhibits acute Meth–induced hyperlocomotion in rats. In the current study, the behavioral experiment revealed pretreatment with 60 mg/kg and 180 mg/kg MEGR dose–dependently attenuated Meth–induced enhanced locomotor activities in rats, in addition, the neurochemical analysis exhibited 180 mg/kg MEGR almost completely blocked the acute Meth–induced increase of accumbal DA and DOPAC levels. These findings suggest that MEGR blocks Meth–induced hyperlocomotion through inhibiting elevated DA synthesis and utilization in the Nacc.

Convincing evidence has highlighted the pharmaceutical values of extracts from traditional Oriental herbs in treating abused drug disorders, in particular, several laboratories have reported extracts of tonic herbs have preventive effects against the rewarding effects of abused drugs [15]. For example, Kim et al. [16] have reported ginsenosides Rb1 and Rg1 blocks Meth–induced behavioral hyperactivity and conditioned place preference (CPP) in rats, Mattioli et al. [17] have demonstrated a Rhodiola rosea L. hydroalcoholic extract prevents establishment of morphine–induced CPP and facilitates extinction of established CPP. In the present study pretreatment with MEGR prevents Meth–induced hyperlocomotion related to the rewarding effects of Meth. This result suggests that MEGR may have therapeutic effects against Meth addition.

Administration of Meth increases extracellular DA levels [18] in the Nacc by (1) up–regulating tyrosine hydroxylase, the rate–limiting step in DA synthesis, (2) inducing reverse transport of monoamines, (3) blocking the activity of the intracellular vesicular monoamine transporter 2, (4) decreasing the expression of the DA transporter (DAT) at the cell surface [19, 20]. The released DA activates DA receptors on accumben GABAergic medium spiny neurons and promotes sensitivities of DA receptors, which appear to be the main biological basis for Meth–induced hyperlocomotion and rewarding effects [21]. Therefore, either inhibiting DA release or dampening DA sensitivity in the Nacc can counteract psychostimulant effects of Meth on locomotion, further abrogate rewarding effects of Meth. In the above mentioned study, Kim et al. have also demonstrated the therapeutic effect of ginsenosides on Meth–induced behavioral abnormalities is mediated by inhibiting accumben postsynaptic DA receptors supersensitivity [16]; in another study, Egecioglu et al. have reported the glucagon–like peptide 1 agonist exendin–4 attenuates cocaine–induced hyperlocomotion by reducing accumbal DA release [22]. In a previous study we demonstrated that MEGR can suppress acute cocaine–induced increase of extracellular DA release in the Nacc [12]. In the current study, we found pretreatment with MEGR almost completely reversed acute Meth–induced enhanced DA synthesis and utilization in rat accumbal tissues. Taken together, these results suggest that the blockade effect of MEGR on Meth–induced hyperlocomotion may be mediated through inhibiting accumbal DA synthesis and utilization.

In summary, in the present study, we have found pretreatment with MEGR significantly
attenuates acute Meth-induced hyperlocomotion and inhibits Meth-induced enhanced DA synthesis and utilization in the Nacc. These results suggest that MEGR may be effective in treating Meth addiction, possibly by modulating DAergic neurotransmissions in the Nacc.

**Acknowledgements**

This study was supported by the National Research Foundation of Korea (NRF) funded by Korea government (MSIP) (No. 2011-0030124) and the Natural Science Foundation of Heilongjiang Province for Returned Scholars, China (LC201028).

**References**

13. Lee MJ, Yang CH, Jeon JP, Hwang M. Protective effects of isoliquiritigenin against methamphetamine-induced neurotoxicity in


